Trial Profile
Apatinib Combined Capecitabine Versus Capecitabine Alone for Adjuvant Therapy in Patients After Biliary Carcinoma Surgery: a Prospective Randomized Controlled Study
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Rivoceranib (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 05 Aug 2018 New trial record